Pharma Industry Challenges/Perspective Symposium
August 9, 2011
Special Function Dinning Room
Lilly Corporate Center, Eli Lilly and Company
Indianapolis, IN 46285
Poster set up (76 mezzanine) 3:30 – 4:00 pm
Poster viewing/Social(76 mezzanine) 4:00 – 6:00 pm
Dinner (SFDR RmB or C) 6:00 – 6:45 pm
Seminar Introduction (SFDR RmA) 7:0 – 7:05 pm
Speaker 1 7:05 – 7:45 pm
Speaker 2 7:45 – 8:25 pm
Poster Winner Introduction 8:25 – 8:30 pm
Poster Award winners presendation 8:30 -9:00 pm
(10 minutes each for 3 people)
Speaker 1: Dr. Pete Kissinger, Professor of Chemistry at Purdue, Chairman of Phlebotics, Inc. and Chairman Emeritus at Bioanalytical Systems, Inc.
Topic: “The pharmaceutical industry then, now and in the future”
Abstract: The age of infectious disease (1950s), the age of chronic high volume disease (1970-1995), the age of cancer (1995-), the age of mergers (1995-2010), the age of accelerating disintegration (2010- ). Where have all the science jobs gone?.
Speaker 2: Dr. Richard Bergstrom. formerly a Research Fellow PK/PD Scientist at Eli Lilly and Company; is Professor of Pharmaceutical Sciences and Director of Research Alliances, Butler University College of Pharmacy and Health Sciences; Adjunct Professor of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine; and Principal of RFBergstrom PK/PD Consulting LLC, Indianapolis, IN.
Topic: “Zero Order, First Order, or Broken Order? A PK/PD View of the Future of Drug Discovery and Development”
Abstract: What does the future hold for drug discovery and development and for pharmaceutical scientists?This is basically a problem of “prediction”. The modern-day PK/PD approach used for prediction is a thoughtful and careful application of modeling and simulation based upon robust assumptions and fundamentally sound scientific principles. Nonetheless, I do not portend that anyone can really accurately predict the future of drug discovery and development in specific terms. Is it harder or easier; more or less complex? It is not even obvious that we know the right model. Yet there are clear signals that the traditional methods of drug discovery and development as we have come to know and trust them are changing radically or perhaps are even broken beyond repair. What then is to become of the pharmaceutical scientist and the endeavor they so nobly engage?.
For more information on the program and poster session, please click here